Exploring Undiscovered Gems in Asia July 2026

In July 2026, the Asian markets are experiencing a dynamic landscape, with geopolitical tensions and fluctuating oil prices impacting investor sentiment across the region. Despite these challenges, certain small-cap stocks have shown resilience and potential for growth, capturing the attention of investors seeking opportunities beyond traditional large-cap investments. In this environment, identifying promising stocks involves looking for companies with robust fundamentals that can navigate economic uncertainties while capitalizing on regional growth trends.

Top 10 Undiscovered Gems With Strong Fundamentals In Asia

Name	Debt To Equity	Revenue Growth	Earnings Growth	Health Rating
CNMC Goldmine Holdings	0.84%	32.52%	78.36%	★★★★★★
DeHua TB New Decoration MaterialLtd	0.63%	1.50%	2.14%	★★★★★★
Beijing Chunlizhengda Medical Instruments	NA	-2.67%	-10.59%	★★★★★★
FINDEX	NA	8.26%	22.39%	★★★★★★
Management SolutionsLtd	10.02%	26.20%	33.40%	★★★★★★
SPRIX	11.35%	8.50%	-9.69%	★★★★★★
Zhejiang Jolly PharmaceuticalLTD	21.31%	17.83%	29.70%	★★★★★☆
Sing Investments & Finance	0.15%	7.06%	8.65%	★★★★☆☆
Shengda ResourcesLtd	54.08%	7.99%	3.75%	★★★☆☆☆
Kexing Biopharm	81.10%	3.69%	0.01%	★★★☆☆☆

Click here to see the full list of 116 stocks from our Asian Undiscovered Gems With Strong Fundamentals screener.

We'll examine a selection from our screener results.

Zibuyu Group (SEHK:2420)

Simply Wall St Value Rating: ★★★★★☆

Overview: Zibuyu Group Limited is an investment holding company that functions as a cross-border e-commerce entity in China, serving markets in North America, Asia, Europe, and beyond, with a market cap of HK$1.98 billion.

Operations: The company's primary revenue stream is derived from online retailers, generating CN¥4.66 billion.

Zibuyu Group, a promising player in the Asian market, has shown impressive earnings growth of 78.6% over the past year, outpacing the Specialty Retail industry's 21.8%. The company trades at 28.8% below its estimated fair value, suggesting potential for investors seeking undervalued opportunities. With a high level of non-cash earnings and sufficient cash to cover its debt obligations, Zibuyu's financial health seems robust. Additionally, their recent dividend increase to HKD 0.23 per share indicates confidence in future performance and shareholder returns, aligning with forecasts projecting a 22.73% annual earnings growth rate moving forward.

• Take a closer look at Zibuyu Group's potential here in our health report.

• Evaluate Zibuyu Group's historical performance by accessing our past performance report.

Kexing Biopharm (SHSE:688136)

Simply Wall St Value Rating: ★★★☆☆☆

Overview: Kexing Biopharm Co., Ltd. is a biopharmaceutical company involved in the research, development, production, and sale of recombinant protein drugs and microecological preparations across several international markets including China, the European Union, Brazil, the Philippines, and Indonesia with a market cap of approximately CN¥3.43 billion.

Operations: Kexing Biopharm generates revenue primarily from pharmaceutical manufacturing, amounting to CN¥1.46 billion. The company's net profit margin is a key financial metric to observe for insights into profitability trends.

Kexing Biopharm, a notable player in the biotech sector, is making strides with its innovative drug pipeline. Despite a net loss of CN¥17.94M in Q1 2026 compared to a profit last year, the company is pushing forward with promising developments like GB10 Injection for eye diseases. This high-concentration ophthalmic drug aims to improve patient compliance by extending dosing intervals. Kexing's strategic alliances and collaborations are enhancing its global reach and biosimilar development capabilities, while trading at 25.8% below estimated fair value suggests potential undervaluation amidst industry challenges and volatile share prices recently observed.

• Click to explore a detailed breakdown of our findings in Kexing Biopharm's health report.

• Gain insights into Kexing Biopharm's past trends and performance with our Past report.

Huatu Cendes (SZSE:300492)

Simply Wall St Value Rating: ★★★★☆☆

Overview: Huatu Cendes CO., LTD, with a market cap of CN¥5.72 billion, is an architectural design company offering non-degree vocational training and architectural engineering design and consulting services to various enterprises and government agencies in China.

Operations: Huatu Cendes generates revenue primarily from architectural engineering design and consulting services, as well as non-degree vocational training. The company focuses on serving state-owned enterprises, private enterprises, multinational corporations, and government agencies in China.

Huatu Cendes, a dynamic player in the professional services sector, has shown robust earnings growth of 136% over the past year, outperforming the industry's -0.9%. Its debt-to-equity ratio climbed to 133.7% in five years, yet it maintains more cash than total debt. Recent financials reveal net income at CNY 240.62 million for 2025, up from CNY 52.99 million previously, with basic earnings per share rising to CNY 0.88 from CNY 0.27 a year ago. Trading at nearly half its estimated fair value suggests potential upside while its EBIT covers interest payments comfortably at a multiple of 35x.

• Get an in-depth perspective on Huatu Cendes' performance by reading our health report here.

• Gain insights into Huatu Cendes' historical performance by reviewing our past performance report.

Where To Now?

• Explore the 116 names from our Asian Undiscovered Gems With Strong Fundamentals screener here.
• Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
• Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com